Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Rhea-AI Summary
Keros Therapeutics (Nasdaq: KROS) announced that CEO Jasbir S. Seehra, Ph.D., will present at three healthcare conferences in late February and March 2026: Oppenheimer (Feb 25), TD Cowen (Mar 3) and Leerink Partners (Mar 10).
Each presentation format is listed (corporate presentation or fireside chat) and archived replays will be available on the company investor website for up to 90 days after each event.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves, with names like ANAB, RIGL and TYRA up while PVLA and BCAX are down, indicating no clear sector-wide trend aligned with KROS’s slight decline.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 20 | Tender offer results | Positive | +3.4% | Final results of cash tender offer completing capital return program. |
| Nov 19 | Tender offer prelim | Positive | -3.9% | Preliminary tender offer results and expected share repurchase details. |
| Nov 05 | Q3 2025 earnings | Positive | +0.6% | Reduced net loss, strong cash, and advancing Takeda and KER-065 programs. |
| Oct 20 | Tender offer launch | Positive | +9.8% | Commencement of cash tender offer under capital return program. |
| Oct 15 | Capital return plan | Positive | -4.0% | Agreements to repurchase shares and outline of $375M capital return plan. |
Recent news has focused on capital return and tender offers, with generally positive reactions but some notable divergences around tender details.
Over the past few months, Keros emphasized shareholder returns via a $375 million capital return program, including issuer tender offers at $17.75 per share and related director and fund transactions. Q3 2025-11-05 results highlighted a sharply reduced net loss and substantial cash, alongside Takeda-partnered and internal pipeline plans. The current conference participation update follows this capital return and earnings phase, positioning management to communicate strategy and clinical progress to investors after major buyback activity.
Market Pulse Summary
This announcement outlines upcoming conference appearances where Keros’s CEO will present the company’s story and pipeline, with replays available for up to 90 days. Against a backdrop of prior capital return initiatives and strengthened cash reported in late 2025, these events give management a platform to update investors on strategic and clinical progress. Key factors to watch include any new data, partnership developments, or changes in long-term plans communicated during these presentations.
Key Terms
transforming growth factor-beta medical
AI-generated analysis. Not financial advice.
LEXINGTON, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences:
Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Date and Time: Wednesday, February 25, 2026 at 11:20 a.m. Eastern time
- Link: https://event.summitcast.com/view/CTtthLh2Bi2D9aYoKpvtEv/V8otRzLTXb58JhbhcNWND2
- Format: Corporate Presentation
TD Cowen 46th Annual Health Care Conference
- Date and Time: Tuesday, March 3, 2026 at 9:50 a.m. Eastern time
- Link: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/gAsAzarzXsTWnurjwhWYFM
- Format: Fireside Chat Presentation
Leerink Partners Global Healthcare Conference
- Date and Time: Tuesday, March 10, 2026 at 1:00 p.m. Eastern time
- Link: https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/4HAHET37grTuDD8oiMF2x7
- Format: Fireside Chat Presentation
For each presentation, an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of each event.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept (KER-065), is being developed for the treatment of Duchenne muscular dystrophy and for the treatment of amyotrophic lateral sclerosis. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.
Contacts
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
Media Contact:
Mahmoud Siddig / Adam Pollack / Viveca Tress
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
FAQ
When will Keros Therapeutics (KROS) present at the Oppenheimer Healthcare Life Sciences Conference?
What format is the KROS presentation at the TD Cowen 46th Annual Health Care Conference on March 3, 2026?
Where can investors watch the archived replays of Keros Therapeutics (KROS) conference presentations?
Who will represent Keros Therapeutics (KROS) at the March 10, 2026 Leerink Partners Global Healthcare Conference?
How long will Keros Therapeutics (KROS) keep conference presentation replays online after each event?
How can investors access live links for Keros Therapeutics (KROS) presentations scheduled in Feb–Mar 2026?
